Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 3Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Endocrine 4NET 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Serotonin Syndrome 1Pancreatic Neoplasms 1Neoplasms 1Diarrhea 1Carcinoid Tumor 1Cachexia 1

Interventions

telotristat ethyl 3lutetium Lu 177 dotatate 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1pasireotide 1gallium Ga 68 dotatate 1Tretinoin 1Temozolomide 1Isotretinoin 1Introns 1Everolimus 1Diazoxide 1Capecitabine 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × telotristat ethyl × NET × Clear all
NCT04713202 2023-02-10

NET-PACS

Big Ten Cancer Research Consortium

Phase 2 Withdrawn
EndocrineNET

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

University of Chicago

Phase 2 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT04034745 2020-12-30

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Cedars-Sinai Medical Center

Withdrawn
EndocrineGastrointestinalNET

Cachexia, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡